Pancreatic Ductal Adenocarcinoma Clinical Trials in Milwaukee, Wisconsin

5 studies are recruiting for pancreatic ductal adenocarcinoma in Milwaukee, Wisconsin right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

   Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Milwaukee, Wisconsin

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT06218914 on ClinicalTrials.gov

2. Pancreatic Cancer Detection Consortium

   This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Medical College of Wisconsin, Milwaukee, Wisconsin

   Locations

   11 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06388967 on ClinicalTrials.gov

3. A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

   This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combinati…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin

   Run by

   Mandana Kamgar, MD

   See if you can join NCT05630989 on ClinicalTrials.gov

4. Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

   The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Medical College of Wisconsin, Milwaukee, Wisconsin

   Locations

   5 in total

   Run by

   Gulam Manji

   See if you can join NCT06048484 on ClinicalTrials.gov

5. Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

   The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadju…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin

   Locations

   93 in total

   Run by

   Panbela Therapeutics, Inc.

   See if you can join NCT05254171 on ClinicalTrials.gov